17 January 2012 - Swiss research and development company, Pevion Biotech AG, unveiled on Tuesday new data from the clinical study of its therapeutic Candida vaccine PEV7, which demonstrate generation of specific and functional B cell memory in 100% of vaccinated volunteers.

The results also confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong and long-lasting immunity in humans even in cases of otherwise weak antigens.

After the company announced positive safety and immunogenicity results of PEV7 earlier, it decided to further investigate the vaccine-induced generation of B cell memory. Therefore, 50% of the volunteers vaccinated with the intramuscular low dose of PEV7 received a single booster immunisation fourteen months after the primary vaccination course. All volunteers showed a rapid response either in serum or in cervicovaginal secretion or in both, after antibody titers had come down to baseline six months prior to the boost in this low-dose group.